

Page 9, line 7, immediately after "(+)" please insert -- with SEQ ID Nos.: 7 and 11 --.

Page 9, line 9, immediately after "(+)" please insert -- with SEQ ID Nos.: 7 and 11 --.

Page 9, line 12, immediately after "(+)" please insert -- with SEQ ID Nos.: 7 and 11 --.

Page 9, line 13, immediately after "(+)" please insert -- with SEQ ID Nos.: 8, 9, 10, 7 and 11 --.

Page 160, line 22, immediately after "(TGC ATG CCT GCA GGT C)" please insert -- (SEQ ID NO:84) --.

In the Claims:

1. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus [is capable of infecting] infects human cells and is resistant to degradation by human complement.

6. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus preparation is resistant to degradation by human complement and [is capable of inducing] induces long term systemic expression of human factor VIII when administered intravenously to a human afflicted with hemophilia A, wherein said long term systemic expression results in a measurable level of recombinant human factor VIII protein being produced in the blood of said human for a period of at least 30 days after the administration of said recombinant retroviral vector preparation.

57. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor IX protein, wherein said recombinant retrovirus [is capable of infecting] infects human cells and is resistant to degradation by human complement.